124 related articles for article (PubMed ID: 21819318)
1. Emerging pathways and future targets for the molecular therapy of pancreatic cancer.
Vaccaro V; Melisi D; Bria E; Cuppone F; Ciuffreda L; Pino MS; Gelibter A; Tortora G; Cognetti F; Milella M
Expert Opin Ther Targets; 2011 Oct; 15(10):1183-96. PubMed ID: 21819318
[TBL] [Abstract][Full Text] [Related]
2. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
3. Targeting Notch signaling in pancreatic cancer.
Ristorcelli E; Lombardo D
Expert Opin Ther Targets; 2010 May; 14(5):541-52. PubMed ID: 20392166
[TBL] [Abstract][Full Text] [Related]
4. Targeting Notch signaling in pancreatic cancer patients--rationale for new therapy.
Mysliwiec P; Boucher MJ
Adv Med Sci; 2009; 54(2):136-42. PubMed ID: 19758972
[TBL] [Abstract][Full Text] [Related]
5. Biology of colorectal cancer.
Saif MW; Chu E
Cancer J; 2010; 16(3):196-201. PubMed ID: 20526096
[TBL] [Abstract][Full Text] [Related]
6. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy.
Holcomb B; Yip-Schneider M; Schmidt CM
Pancreas; 2008 Apr; 36(3):225-35. PubMed ID: 18362834
[TBL] [Abstract][Full Text] [Related]
7. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer.
Nakashima H; Nakamura M; Yamaguchi H; Yamanaka N; Akiyoshi T; Koga K; Yamaguchi K; Tsuneyoshi M; Tanaka M; Katano M
Cancer Res; 2006 Jul; 66(14):7041-9. PubMed ID: 16849549
[TBL] [Abstract][Full Text] [Related]
8. Targeting embryonic signaling pathways in cancer therapy.
Harris PJ; Speranza G; Dansky Ullmann C
Expert Opin Ther Targets; 2012 Jan; 16(1):131-45. PubMed ID: 22239436
[TBL] [Abstract][Full Text] [Related]
9. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy.
Wang Z; Ahmad A; Li Y; Azmi AS; Miele L; Sarkar FH
Anticancer Res; 2011 Apr; 31(4):1105-13. PubMed ID: 21508353
[TBL] [Abstract][Full Text] [Related]
10. Development of the pancreas and pancreatic cancer.
Lewis BC
Endocrinol Metab Clin North Am; 2006 Jun; 35(2):397-404, xi. PubMed ID: 16632101
[TBL] [Abstract][Full Text] [Related]
11. Core signaling pathways and new therapeutic targets in pancreatic cancer.
You L; Chen G; Zhao YP
Chin Med J (Engl); 2010 May; 123(9):1210-5. PubMed ID: 20529565
[TBL] [Abstract][Full Text] [Related]
12. Signal transduction in human pancreatic cancer: roles of transforming growth factor beta, somatostatin receptors, and other signal intermediates.
Li M; Becnel LS; Li W; Fisher WE; Chen C; Yao Q
Arch Immunol Ther Exp (Warsz); 2005; 53(5):381-7. PubMed ID: 16314822
[TBL] [Abstract][Full Text] [Related]
13. New treatment options for advanced pancreatic cancer.
Middleton G; Ghaneh P; Costello E; Greenhalf W; Neoptolemos JP
Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):673-96. PubMed ID: 19072345
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of pancreatic cancer and clinical perspectives.
Matthaios D; Zarogoulidis P; Balgouranidou I; Chatzaki E; Kakolyris S
Oncology; 2011; 81(3-4):259-72. PubMed ID: 22116519
[TBL] [Abstract][Full Text] [Related]
15. Requirement of NEMO/IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas.
Maier HJ; Wagner M; Schips TG; Salem HH; Baumann B; Wirth T
Oncogene; 2013 May; 32(21):2690-5. PubMed ID: 22751123
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs in the treatment of pancreatic cancer.
Mahalingam D; Kelly KR; Swords RT; Carew J; Nawrocki ST; Giles FJ
Expert Opin Emerg Drugs; 2009 Jun; 14(2):311-28. PubMed ID: 19466902
[TBL] [Abstract][Full Text] [Related]
17. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032
[TBL] [Abstract][Full Text] [Related]
18. Future strategies for targeted therapies and tailored patient management in pancreatic cancer.
Ko AH
Semin Oncol; 2007 Aug; 34(4):354-64. PubMed ID: 17674964
[TBL] [Abstract][Full Text] [Related]
19. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.
Sakorafas GH; Tsiotou AG; Tsiotos GG
Cancer Treat Rev; 2000 Feb; 26(1):29-52. PubMed ID: 10660490
[TBL] [Abstract][Full Text] [Related]
20. Drugs in preclinical and early-stage clinical development for pancreatic cancer.
Asuthkar S; Rao JS; Gondi CS
Expert Opin Investig Drugs; 2012 Feb; 21(2):143-52. PubMed ID: 22217246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
